Hutch News

Hutch News

Stories tagged 'gvhd'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 4, 2018

Increasing access to stem cell transplants; improving survival, QOL for those with scleroderma; biostatistician named chair-elect of AAAS Section on Statistics.

View story >

Fred Hutch/SCCA transplant patient survival above the expected rate in U.S.

For 5th year in a row, bone marrow transplant program receives top recognition

Dec. 22, 2017 | By Molly McElroy

For the fifth year in a row, the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has been recognized by the Center for International Blood and Marrow Transplant Research as exceeding expectations for one-year survival rates. These survival rates specifically pertain to patients who have received transplants of blood-forming stem cells from healthy donors, a procedure pioneered at Fred Hutch.

View story >

Stem cell transplantation physician-scientist recruited from Australia to join Fred Hutch, SCCA

Dr. Geoffrey Hill will help integrate bone marrow transplantation with emerging cancer immunotherapies

Dec. 7, 2017 | By Molly McElroy

Fred Hutchinson Cancer Research Center is appointing world-renowned blood stem cell transplantation physician-scientist Dr. Geoffrey Hill to be director of Hematopoietic Stem Cell Transplantation, effective July 1.

View story >

'Back to normal life'

Sorting stem cells before transplant helps lower the risk of graft-vs.-host disease, researcher reports

Dec. 5, 2016 | By Bill Briggs / Fred Hutch News Service

Patients in a clinical trial, including Dr. Curtis Mack, had lower rates of graft-vs.-host disease when researchers filtered stem cells before transplant, scientists reported Monday.

View story >

Three's a charm in a triple-drug combination for transplant patients

A drug with a storied past offers a new edge against an old foe

Dec. 4, 2016 | By Sabin Russell / Fred Hutch News Service

Discovered nearly 45 years ago in the volcanic soils of fabled Easter Island in the Pacific, a drug first thought of as an antifungal agent has found a new purpose by boosting the survival of leukemia patients after blood stem cell transplants. In a clinical trial conducted by Fred Hutchinson Cancer Research Center, the addition of a third drug, sirolimus, to a standard two-drug regimen effectively cut in half the incidence of acute graft-vs.-host disease, or GVHD, a common and dangerous complication of these lifesaving procedures.

View story >

The cost of survival

Treatment complications can impact lives for years after cure but some cancers survivors are reluctant to reveal their pain

Nov. 4, 2016 | By Bill Briggs / Fred Hutch News Service

Some survivors say it’s hard for those untouched by cancer to understand the scales of life don’t always balance with survival on one side and a jumble of complications heaped on the other.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.